Cargando…
Long-term follow-up of patients treated with dupilumab for chronic spontaneous urticaria: A case report
Several therapeutic strategies have been established to achieve maximal remission and improve quality of life in patients with chronic spontaneous urticaria. We previously reported dupilumab as a novel therapy for antihistamine-refractory chronic spontaneous urticaria patients who failed to respond...
Autores principales: | Abadeh, Armin, Lee, Jason Kihyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386812/ https://www.ncbi.nlm.nih.gov/pubmed/35991950 http://dx.doi.org/10.1177/2050313X221117702 |
Ejemplares similares
-
Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease
por: Abadeh, Armin, et al.
Publicado: (2022) -
Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023) -
Successful treatment of exfoliative cheilitis with dupilumab: A case report
por: Cino, Daniela, et al.
Publicado: (2023) -
Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report
por: Kim, Ho Seung, et al.
Publicado: (2020) -
The prevalence of gastrointestinal symptoms and cobalamin deficiency in patients with chronic urticaria
por: Abadeh, Armin, et al.
Publicado: (2023)